# Eisai Co., Ltd. clinical trials: 152 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 152 trials with Eisai Co., Ltd. as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Eisai Co., Ltd.: 152 rows for $7.60, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/eisai-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 152
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 152, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 7, 2026 | NCT07515014 | A Study of E6742 in Participants With Systemic Lupus Erythematosus | Eisai Co., Ltd. | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515014) |
| January 27, 2025 | NCT06793709 | A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor... | Eisai Co., Ltd. | Observational | Recruiting | Biliary Tract Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06793709) |
| October 24, 2024 | NCT06657378 | A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic... | Eisai Co., Ltd. | Observational | Recruiting | Partial-Onset Seizures, Primary Generalized Tonic-clonic Seizures | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06657378) |
| March 21, 2024 | NCT06322667 | A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab | Eisai Co., Ltd. | Observational | Recruiting | Alzheimer's Disease | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06322667) |
| December 1, 2022 | NCT05633108 | A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders | Eisai Co., Ltd. | Observational | Completed | Psychotic Disorders | 579,728 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05633108) |
| October 26, 2022 | NCT05594589 | A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder | Eisai Co., Ltd. | Phase 2 | Completed | Sleep Initiation and Maintenance Disorders | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05594589) |
| March 14, 2022 | NCT05278676 | A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants | Eisai Co., Ltd. | Phase 1 | Completed | Healthy Volunteers | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05278676) |
| March 14, 2022 | NCT05278663 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants | Eisai Co., Ltd. | Phase 1/2 | Completed | Lupus Erythematosus, Systemic | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05278663) |
| February 8, 2022 | NCT05228158 | A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2)... | Eisai Co., Ltd. | Observational | Active not recruiting | Lymphoma, Follicular | 145 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05228158) |
| August 16, 2021 | NCT05007392 | A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout | Eisai Co., Ltd. | Phase 3 | Completed | Gout | 451 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05007392) |
| January 26, 2021 | NCT04724109 | A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With... | Eisai Co., Ltd. | Observational | Completed | Parkinson Disease | 1,088 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04724109) |
| December 24, 2020 | NCT04683185 | A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants | Eisai Co., Ltd. | Phase 1 | Completed | Healthy Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04683185) |
| October 30, 2020 | NCT04609852 | A Study to Assess the Safety and Tolerability of E8001 in Healthy Male Participants | Eisai Co., Ltd. | Phase 1 | Completed | Healthy Volunteers | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04609852) |
| October 5, 2020 | NCT04573556 | A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia. | Eisai Co., Ltd. | Observational | Completed | Sleep Initiation and Maintenance Disorders | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04573556) |
| October 1, 2020 | NCT04572295 | A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and... | Eisai Co., Ltd. | Phase 1 | Completed | Breast Neoplasms | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04572295) |
| September 29, 2020 | NCT04568902 | Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast... | Eisai Co., Ltd. | Phase 1 | Completed | Breast Neoplasms | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04568902) |
| September 25, 2020 | NCT04565574 | A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in... | Eisai Co., Ltd. | Phase 1 | Completed | Healthy Participants | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04565574) |
| September 21, 2020 | NCT04555733 | A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants | Eisai Co., Ltd. | Phase 1 | Completed | Healthy Volunteer | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04555733) |
| September 16, 2020 | NCT04549168 | A Study of Lemborexant in Chinese Participants With Insomnia Disorder | Eisai Co., Ltd. | Phase 3 | Completed | Sleep Initiation and Maintenance Disorders | 194 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04549168) |
| February 17, 2020 | NCT04271488 | Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and... | Eisai Co., Ltd. | Phase 1 | Recruiting | Hepatic Impairment | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04271488) |
| January 23, 2020 | NCT04238715 | A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR)... | Eisai Co., Ltd. | Phase 2 | Completed | Cholangiocarcinoma | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04238715) |
| January 18, 2020 | NCT04230044 | A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy | Eisai Co., Ltd. | Observational | Completed | Epilepsy, Partial-onset Seizures | 117 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04230044) |
| September 6, 2019 | NCT04078295 | A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor | Eisai Co., Ltd. | Phase 1/2 | Active not recruiting | Solid Neoplasms | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04078295) |
| July 5, 2019 | NCT04008082 | A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma | Eisai Co., Ltd. | Observational | Completed | Carcinoma, Hepatocellular, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms | 412 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04008082) |
| March 22, 2019 | NCT03885882 | A Pharmacokinetic (PK) Study of Three Types of E0302 Sustained Release (SR) Tablets Compared With E0302 Immediate Release (IR) Tablet Under... | Eisai Co., Ltd. | Phase 1 | Completed | Healthy Subjects | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03885882) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 54 |
| Phase 1/2 | 5 |
| Phase 2 | 25 |
| Phase 2/3 | 6 |
| Phase 3 | 20 |
| Phase 4 | 9 |
| Not applicable | 1 |
| Observational | 32 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 139 |
| Recruiting | 5 |
| Active not recruiting | 4 |
| Terminated | 4 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 13 |
| Seizures | 10 |
| Epilepsy | 9 |
| Alzheimer Disease | 8 |
| Sleep Initiation and Maintenance Disorders | 8 |
| Breast Neoplasms | 7 |
| Dementia | 7 |
| Carcinoma, Hepatocellular | 6 |
| Arthritis, Rheumatoid | 5 |
| Stomach Ulcer | 5 |
| Lewy Body Disease | 5 |
| Carcinoma | 4 |
| Torticollis | 3 |
| Duodenal Ulcer | 3 |
| Gastroesophageal Reflux | 3 |
| Amyotrophic Lateral Sclerosis | 3 |
| Cognitive Dysfunction | 3 |
| Recurrence | 3 |
| Stomach Neoplasms | 3 |
| Lymphoma, Follicular | 2 |
| Gastrointestinal Neoplasms | 2 |
| Acrocephalosyndactylia | 2 |
| Esophagitis, Peptic | 2 |
| Sarcoma | 2 |
| Lupus Erythematosus, Systemic | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Chimney sweeps in the United States](https://specstream.ai/data/businesses/chimney-sweeps/united-states)
- [Web hosting companies in the United States](https://specstream.ai/data/businesses/web-hosting-companies/united-states)
- [Private investigators in the United States](https://specstream.ai/data/businesses/private-investigators/united-states)
- [International fusion restaurants in the United States](https://specstream.ai/data/businesses/international-fusion-restaurants/united-states)
- [Dim sum restaurants in the United States](https://specstream.ai/data/businesses/dim-sum-restaurants/united-states)
- [Asian restaurants in the United States](https://specstream.ai/data/businesses/asian-restaurants/united-states)
